The effect of a pre- and post-operative exercise programme versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (The PERIOP-OG Trial): Study protocol for a randomised controlled trial.

CURRENT STATUS: UNDER REVIEW

Roisin Tully
Royal College of Surgeons in Ireland
roisintully@rcsi.com

 Corresponding Author
ORCiD: https://orcid.org/0000-0001-6843-2844

Lisa Loughney
ExWell Medical, Santry Sports Link, Dublin

Jarlath C Bolger
Royal College of Surgeons in Ireland, St Stephens Green, Dublin

Jan Sorensen
Royal College of Surgeons in Ireland, St Stephens Green, Dublin

Oliver J Mcanena
Department of Upper GI Surgery, Galway University Hospitals

Chris G Collins
Department of Upper GI Surgery, Galway University Hospitals

Paul A Carroll
Department of Upper GI Surgery, Galway University Hospitals

Mayilone Arumugasamy
Department of Upper GI Surgery, Beaumont Hospital, Dublin

Thomas J Murphy
Department of Upper GI Surgery, Mercy University Hospital, Cork
William B Robb
Department of Upper GI Surgery, Beaumont Hospital, Dublin

DOI:
10.21203/rs.2.19501/v3

SUBJECT AREAS
Integrative & Complementary Medicine   Translational Medicine

KEYWORDS
Neoadjuvant Chemoradiotherapy, Exercise Training, Physical Fitness, Quality of Life, Cancer, Oesophagogastric
Abstract
Background: Advances in peri-operative oncological treatment, surgery and peri-operative care have improved survival for patients with oesophagogastric cancers. Neoadjuvant cancer treatment (NCT) reduces physical fitness, which may reduce both compliance and tolerance of NCT as well as compromising post-operative outcomes. This is particularly detrimental in a patient group where malnutrition is common and surgery is demanding. The aim of this trial is to assess the effect on physical fitness and clinical outcomes of a comprehensive exercise training programme in patients undergoing NCT and surgical resection for oesophagogastric malignancies. Methods: The PERIOP-OG trial is a pragmatic, multi-centre, randomised controlled trial comparing a programme of peri-operative exercise with standard care in patients with oesophagogastric cancers treated with NCT and surgery. The intervention group undergo a formal exercise training programme and the usual care group receive standard clinical care (no formal exercise advice). The training programme is initiated at cancer diagnosis, continued during NCT, between NCT and surgery, and then resumed again after surgery. All participants undergo assessments at: baseline, post-NCT, pre-surgery and at 4 and 10 weeks after surgery. The primary endpoint is cardiorespiratory fitness measured by demonstration of a 15% difference in 6-minute walk test assessed at the pre-surgery time point. Secondary endpoints include measures of physical health (upper and lower body strength tests), body mass index, frailty, activity behavior, psychological and health related quality of life outcomes. Exploratory endpoints include a health economics analysis, assessment of clinical health by post-operative morbidity scores, hospital length of stay, nutritional status, immune and inflammatory markers, and response to NCT. Rates of NCT toxicity, tolerance and compliance will also be assessed. Discussion: The PERIOP-OG trial will determine whether, when compared to usual care, exercise training initiated at diagnosis and continued during NCT, prior to surgery and then during recovery, can maintain or improve cardiorespiratory fitness and other physical, psychological and clinical health outcomes. This trial will inform both the prescription of exercise regimes as well as the design of a larger prehabilitation and rehabilitation trial to investigate whether exercise in combination with nutritional and psychological interventions elicit greater benefits.
Background

Recent advances in peri-operative oncological treatments have led to survival benefits for patients with locally advanced oesophagogastric cancers (1-3). In spite of the benefits, neoadjuvant cancer therapy (NCT), due to its inherent toxicity, can significantly impact on patients’ fitness for subsequent surgical resection (4-6). Reduced physical fitness is associated with poor tolerance of peri-operative oncological treatment, increased toxicity and compromised peri-operative outcomes (4-6). There is evidence that reduced physical fitness in the pre-operative period is also a negative predictor of long-term survival in oesophagogastric cancer (7).

Peri-operative prehabilitation and rehabilitation have been shown to be effective in cardiothoracics, orthopaedics and abdominal cancers (8-10). The widespread use of neoadjuvant therapy in oesophagogastric cancers offers a distinct window during which prehabilitation can be undertaken. This cancer group does however present unique challenges, as patients tend to be older, have pre-existing co-morbidity and often present with nutritional compromise. It is also important that any exercise prescription does not negatively impact upon the physiological reserve of patients undergoing NCT followed by resectional oesophagogastric surgery.

Despite improvements in surgical techniques for oesophagogastric cancer, peri-operative morbidity remains significant (11-15). Post-operative complications result in increased utilisation of critical care, prolonged hospital stay and long-term adverse events (13, 16). Peri-operative morbidity is now also increasingly recognised to be associated with reduced overall and cancer-specific survival (17). Patients who are less physically fit at the time of operation have a higher incidence of post-operative morbidity and mortality (18) and hence any strategy which can reduce physical decline or improve physical conditioning between cancer diagnosis and surgery is worthy of investigation.

Following oesophagogastric cancer surgery rehabilitation efforts appear to improve cardiorespiratory fitness and quality of life without compromising nutritional status (19). How pre-operative programmes impact on patient outcomes is less defined. There is limited evidence that inspiratory muscle, aerobic and resistance training may reduce peri-operative morbidity (20) and both prehabilitation and rehabilitation may improve functional outcomes (20). The optimal peri-operative
exercise strategy remains ill-defined and it is unclear what form exercise interventions should take. It is also unclear whether programmes should be supervised, home-based or a combination of both, and measures of compliance are not established (20). Whilst some evidence exists that health-related quality of life HRQoL may be improved by post-operative exercise programmes (19), data on HRQoL measures from pre-operative interventions has yet to demonstrate significant improvements. A number of small trials and cohort studies are underway which may help to bridge the gap in knowledge (21-27).

The primary aim of the PERIOP-OG trial is to investigate the effects of a community-based exercise training programme, delivered throughout NCT and prior to surgery compared to usual care. The secondary aim is to investigate the same post-operatively for 6 weeks. The trial will comprehensively study the effects of exercise on physical, psychological and clinical health outcomes in patients with locally advanced oesophagogastric cancer undergoing neoadjuvant treatment followed by curative surgery.

Methodology And Study Design
The PERIOP-OG trial is a prospective and pragmatic randomised controlled multi-centre superiority trial that will compare a programme of peri-operative exercise with standard care in patients with oesophagogastric cancer undergoing NCT followed by surgery. The trial will be conducted in 3 university teaching hospitals in Ireland (Beaumont Hospital, Dublin, The Mercy University Hospital, Cork and Galway University Hospital, Galway) with the exercise training programme delivered in 7 exercise centres nationwide. The exercise training is delivered through ExWell Medical which is a chronic illness exercise and rehabilitation service, and its exercise partners nationwide.

Lead exercise personnel perform assessments after receiving standardised training by lead study coordinators (LL and RT).

An algorithm of the clinical pathway and the timepoints for assessments during the trial is shown in Figure 1. Ethical approval for this study has been received in each participating site prior to study commencement and the trial is registered with clinicaltrials.gov (NCT: NCT0380751).

Study Objectives
The primary objective of the PERIOP-OG trial is to demonstrate that a structured community-based exercise programme will result in a clinically significant increase in cardiorespiratory fitness pre-surgery when compared to a standard care control group. Cardiorespiratory fitness will be assessed using a 6-minute walk test (6MWT) at 5 time points in the study – baseline, post NCT, pre-surgery, 4 weeks and 10 weeks after surgery.

Secondary aims of the study include assessing whether exercise training improves other physical health outcomes assessed using upper and lower body strength tests, activity behavior monitoring, body mass index and frailty. Psychological health will be assessed using a series of questionnaires; HRQoL (EQ-5D-5L Health Questionnaire), Functional Assessment of Cancer Therapy (FACT-E), General Self Efficacy (GSE), Mastery (Pearlin Mastery Scale), Surgical Fear Questionnaire (SFQ) and general optimism using the Life Orientation Test-Revised (LOT-R) tool as well as semi structured interviews.

Exploratory end-points include assessment of post-operative morbidity (Clavien-Dindo classification and as agreed by the Esophagectomy Complications Consensus Group (ECCG) (28), the Comprehensive Complication Index, hospital length of stay, nutritional status (serum albumin, sarcopenia score and Foodbook-24), inflammatory markers, cancer staging and response to NCT and a medico-economics analysis of cost effectiveness of the exercise intervention on reducing health care costs and burden. Additionally, rates of NCT toxicity, tolerance and compliance will be measured.

**Participants**

Eligibility criteria include the following: age ≥ 18 years, multidisciplinary team (MDT) referral for neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy prior to oesophagectomy or gastrectomy; confirmed adenocarcinoma or squamous cell cancer of the oesophagus, oesophago-gastric junction or stomach; for oesophageal cancers tumours must be more than 5cm below the crico-pharyngeus muscle.

Exclusion criteria include the following: inability to give informed consent, inability to participate in exercise training (unable to perform 6MWT); patients undergoing primary surgery; distant metastatic disease, previous or concomitant malignancy that would interfere with this treatment protocol and
pregnancy.

**Recruitment and randomisation**

The PERIOP-OG trial is currently recruiting (start date 1\textsuperscript{st} March 2019, proposed end date July 2020). All potentially eligible patients are identified in each centre’s MDT and are approached for inclusion at diagnosis before NCT has started. Eligible patients are given an information leaflet and then 72 hours later are contacted to confirm participation, informed consent is taken and randomisation group revealed. Participants are randomised using central data management to generate a random allocation sequence (1:1). Due to the nature of the study, blinding of patients, data collectors and physiological assessors is not possible but treating surgeons and their teams are blinded to randomisation, as is the primary analyst.

**Nutrition**

Malnutrition is common in patients diagnosed with oesophagogastric cancers. All participants enrolled in the PERIOP-OG trial follow a standardised nutritional pathway of care. All 3 participating centres have specialist dieticians who are highly trained and dedicated to the care of oesophagogastric cancer patients. All patients have a dietician assessment at the time of diagnosis and an individualised dietary plan with appropriate supplementation structured to ensure sufficient calorie and protein supplementation. Pre- and peri-operative feeding adjuncts (percutaneous enteral feeding or total parenteral nutrition) will be recorded on an individual basis.

**Usual care control group**

The usual care control group (no formal exercise training) receive routine care throughout their cancer pathway. No specific advice about exercise training is offered. Activity monitors are worn for a period of 7 days by patients in both groups at each time point of assessment and are used to measure the exercise levels of patients within the control group.

**Exercise intervention group**

The exercise-training programme is started before and continues during NCT. It is continued between NCT and surgery and then resumed for 6 weeks after surgery once patients are deemed clinically fit. The exercise-training programme is based on experience gained from a previous feasibility study
performed by our own team.

Participants in the exercise group will be offered an option to participate in either a centre-based exercise programme (CBEP) or a home-based exercise programme (HBEP). This is to cater for all patients as the time-dense schedules of NCT regimens and the long distances some patients have to travel to their treating hospitals often pose a challenge in exercise prescribing. All participants in the exercise group are provided with a fitbit and a step count log.

The HBEP is offered for patients where access to an exercise centre is difficult due to remote or rural living. HBEP involves undertaking exercise independently and is prescribed at the baseline assessment (Figure 1). Patients are given a home programme pack, which includes a manual exercise handbook, an exercise prescription, a rate of perceived exertion (RPE) scale and a log diary. They are also given a link to an online motivational video developed specifically for the PERIOP-OG Home Programme. Participants are educated in aerobic and resistance exercises and the RPE scale and they complete a 10-minute exercise session on the cycle ergometer under the supervision of their personal trainer. This provides an understanding of what exercise intensity level they should aim to achieve during aerobic exercise at home. Additionally, participants are instructed on resistance exercises (i.e. weight selection, technique, breathing, rest periods). HBEP participants receive a weekly telephone call, using a structured proforma, to assess adherence to the programme and to amend the programme if necessary. Participants feedback their daily step count each week. All conversations and the duration of each phone call are documented in participant case report forms. HBEP compliance is also self-reported by the participant using a log diary.

The CBEP takes place in 7 exercises centers nationwide. Participants are prescribed exercise on an individual basis following the principles below. Compliance with the CBEP is recorded by number of sessions attended.

**Exercise training protocol**

The delivery of the CBEP and HBEP is described using the FITT principle (frequency, intensity, time and type of exercise training) (29).

Frequency - Participants are asked to undertake 2-3 structured exercise training sessions per week
during NCT and 3 thereafter.

Intensity - Exercise sessions may be interval based or continuous. Interval training involves a series of exercises repeated at moderate and higher intensities and continuous exercise sessions involve moderate intensity continuous exercise for the entire duration of the exercise period.

Participants in either programme with access to gym equipment engage in interval training of moderate and high intensity (13: somewhat hard to 15: hard on the RPE scale). For those unable to undertake interval training or with no access to gym equipment, a continuous exercise training programme is prescribed based on the RPE scale (13: somewhat hard).

Time – The first interval (moderate to high intensity) exercise session is 30 minutes: 5-minute warm-up followed by 4 repeated bouts of moderate intensity (3 min) to high intensity (2 min) intervals and 5-minute cool down. The first continuous exercise session is also 30 minutes duration: 5 minutes warm-up, 20 minutes of continuous moderate intensity exercise and 5 minutes cool down.

The second and subsequent sessions are 40 minutes long: 5 minutes warm-up followed by 6 repeated bouts of moderate intensity (3 minutes) to high intensity (2 minutes) intervals and a 5 minute cool down. The second continuous exercise session is made up of a 5-minute warm-up, 30 minutes of continuous moderate intensity and a 5-minute cool down. Post-operatively, participants resume exercising initially for 20-minute sessions and increase the duration of exercise by 10 minutes per week until the pre-operative timings are achieved.

Type - CBEP or HBEP participants with access to gym equipment may include the use of any of the following equipment: upright cycle ergometer; recumbent cycle ergometer; treadmill; elliptical ergometer; and rowing ergometer, depending on patient preference. HBEP participants without gym access, may use a combination of walking, jogging or cycling.

Resistance training involves a circuit of 6-10 stations alternating upper and lower body exercises using dumb-bells as outlined in the home-based exercise manual handbook.

Progression - During NCT, there is no progression in exercise intensity. In the time window between completing NCT and surgery, exercise intensity is progressed every 5 sessions. Post-operatively, exercise is progressed by time (as previously outlined) and also by intensity 8 weeks following
surgery.

Outcome Measurements

Primary Outcome:

Cardiorespiratory Fitness

The primary outcome is measurement of cardiorespiratory fitness using the 6MWT measured at baseline assessment and prior to surgery. The 6MWT is performed with participants walking up and down a 20 meter course marked by cones for 6 minutes under instruction to cover as much ground as possible. The number of laps completed is recorded. A standard set of instructions is used as per the European Respiratory Society guidelines. The 6MWT is a validated assessment of cardiorespiratory function in clinical populations (30, 31). A systematic review in 2016 demonstrated that field tests may be able to predict post operative outcome however further validation work is merited (32).

Secondary Outcomes:

Physical Health

Strength:

i. The sit to stand test. Participants sit on a chair (height 43-45 cm) with arms crossed across their chest, feet flat on the floor, parallel to each other, and approximately shoulder width apart. Participants then stand up and sit down 10 times as quickly as possible and must fully extend their legs on each stand. The time taken to perform 10 repetitions will be timed. Participants will perform two trials and the best trial will be recorded as their score (33).

ii. The handgrip test. This is measured using a hand dynamometer (Takei 5401 Hand Grip Dynamometer (Digital)). The test is conducted in a standing position with the upper arm tight against the participant’s trunk and the forearm at a right angle to the upper arm. The gripping handle is set to a comfortable width to ensure the participant can rest the fat pads of the phalanx of the four fingers on the handle. The participant is instructed to squeeze the handle with maximum force for 5 seconds
and the value recorded. The participant will complete three trials on each hand. The highest score will be recorded (34).

**Activity Behavior**

Physical activity and sedentary behavior is assessed using a 7-day ActivPAL3 triaxial accelerometer. Participants in both groups are instructed to wear this device on the midpoint of the anterior aspect of the right thigh continuously for seven days at the 5 time points of assessment. The accelerometers don’t provide participants with any feedback: data can only be analysed centrally by the lead researchers. Total activity counts per day as well as time in sedentary behavior are recorded for both groups.

**Body Composition**

BMI is calculated in the standard manner.

**Frailty**

Frailty is assessed by the Risk Analysis Index. It has been reported as a valid tool for measuring frailty in surgical populations (35). It provides a prospective, pre-operative assessment of frailty in clinical practice. It provides a score between 0 and 81 taking into account demographic, clinical and independence information.

**Psychological Health:**

This is assessed using a number of validated questionnaires and semi-structured interviews. The questionnaires are as follows;

i. **Life Orientation Test-Revised (LOT-R)** – Assesses optimism and consists of ten items assessing expectancy of positive versus negative outcomes. Higher scores represent higher levels of optimism (36).

ii. **EQ-5D-5L health questionnaire** is a standardised measure of health status developed by the EuroQoL Group in order to provide a simple, generic measure of health for clinical and economic appraisal (37).

iii. **Functional Assessment of Cancer Therapy-Esophageal (FACT-E) questionnaire.** This is
a health-related quality of life instrument validated in patients with esophageal cancer. It is composed of a general component (FACT-G) and an esophageal cancer subscale (ECS) (38).

iv. The Surgical Fear Questionnaire (SFQ) will assess participants fear of surgery and is a validated and reliable eight-item index of surgical fear consisting of 2 subscales: fear of the short-term consequences of surgery and fear of the long-term consequences of surgery (39).

v. General Self Efficacy (GSE) and Mastery (Pearlin Mastery Scale). A highly reliable and validated measurement of self-efficacy. This questionnaire consists of seven items designed to assess psychological coping resources (Mastery) (40).

vi. Semi-structured interviews will explore patients’ perceptions of the surgical pathway.

Exploratory outcomes will include:

Nutritional Status is assessed using the following tools:

i. Glasgow Prognostic Score provides cancer prognosis based on serum biomarkers CRP and Albumin (41).

ii. Foodbook-24, a web-based, dietary tool consisting of a 24 hour dietary recall and food frequency questionnaire (42).

iii. Sarcopenia – Standard care for all patients is to undergo a staging CT scan at the time of diagnosis and then a restaging CT scan after NCT. Sarcopenia will be measured at these 2 time points using SliceOmatic software (Tomovision, Magog, Canada). At the L3 level total skeletal muscle, subcutaneous fat and visceral fat will be measured. Skeletal muscle mass will be calculated as skeletal muscle / height (m)² and will be recorded by two individuals, both of whom will be external to the trial group.

Post-operative Morbidity Outcomes
i. Post-operative Morbidity Score (POMS) is an 18-item tool that addresses morbidity relevant to the post-surgical patient (43).

ii. The Clavien-Dindo classification of surgical complications consists of 7 grades that rank post-operative complication severity (44).

iii. The Comprehensive Complication Index (45) integrates all post-operative complications with their respective severities, on a scale ranging from 0 (no burden from complications) to 100 (death).

iv. Patients undergoing oesophagectomy will have post-operative morbidity recorded as per the Esophagectomy Complications Consensus Group (28) mortality will be assessed at 30 days and 90 days.

**Blood Markers of Inflammation**

C- reactive protein and white cell count will be measured.

**Health Economic Outcomes**

An exploratory analysis will be made of the cost of the exercise intervention and the net monetary benefit on health care costs and health care interactions arising during the time period of the study will be calculated.

**NCT Toxicity**

Rates of NCT toxicity, tolerance and compliance will be collected.

**Patient and Public Involvement (PPI)**

Patient and public volunteers are members of the trial steering committee and their experience and input was used to help shape the study design. Volunteers attend quarterly trial steering meetings and receive monthly newsletters and trial management meeting minutes. They will assist with trial delivery and conduct as well as trial reporting. Additionally, they guide our dissemination plan using social media, presentation at conferences, dissemination to patient advocacy groups and journal articles.

**Safety**
Adverse events are recorded in the relevant case report form by the lead site researcher. Fatal or life-threatening serious adverse events are reported within 24 hours of the research team becoming aware of the event. The serious adverse events form documents the nature of the event, date of onset, severity, corrective therapies given, outcome and causality (i.e. unrelated, unlikely, possibly, probably, definitely). Any queries relating to adverse event reporting will be directed to the principal investigator.

**Data analysis**

**Sample size calculation**

The sample size calculation was based on results from a recent publication by Minnella et al (46) which identified a pre-operative increase in 6MWT of 60m from a baseline score of 450m - an approximate 13% improvement. Assuming a similar baseline score, a 15% difference can be detected with a p-value of 0.05 and power 80% with a sample of 26 participants with full data in the 2 groups. With an anticipated 20% drop out, recruitment of 62 participants is anticipated.

**Statistical Analysis**

The analysis will be performed as an intention-to-treat analysis. No interim analysis will be conducted. Data validity will be conducted prior to analysis and corrected as appropriate.

The study population will be described separately for the two randomised groups using variables obtained at baseline. The variables will be described as mean (SD) and numbers (%) as appropriate. The primary analysis of the primary outcome will be conducted using t-tests of independent group mean differences in 6MWT. The mean difference and 95% confidence interval will be reported and illustrated graphically. Individual change in 6MWT will be calculated from baseline and compared at different time points using t-tests.

The secondary analysis of the primary outcome will use mixed-level analysis with intervention group, time point and interaction of intervention and time points. This analysis will include baseline score for the outcome measure as a covariate. The estimated parameter for the interaction variables will be interpreted as the difference-in-difference between the two groups over time. A separate analysis will explore potential differences in the intervention group between participants who received the
intervention at a training centre and those who trained at home. This analysis will be expanded to include descriptive baseline variables such as sex and age. The secondary analysis will use mixed-level analysis and include baseline score and baseline characteristics as covariates. The cost-effectiveness analysis will be conducted from a societal perspective over the duration of the trial period. No extrapolation of long-term economic outcomes is planned. The EQ-5D-5L data reported at each time point will be used to estimate quality-adjusted life years using time-weighted utility scores. The utility scores will be calculated for each individual at each data point using the Irish scoring algorithm for EQ-5D-5L (47). The area under the curve denotes the QALY and incremental QALY is determined as the mean group difference.

Cost of the intervention and subsequent health care resource use will be calculated for each individual using average cost per participant for the intervention programme and self-reported data on healthcare utilisation. Unit costs will be obtained from national sources and assigned to the resource utilisation and aggregated over the whole trial period for each individual. Net monetary benefit (NMB) will be estimated as the cost minus the QALY gain multiplied by an assumed threshold value per QALY.

**Missing data**

Participants with missing data either because of early drop-out, loss to follow-up or missed participation in the data collection can bias the results. By design there will be no missing data at baseline because only participants with complete baseline data will be randomised. Missing variables in outcome measures will be handled according to instrument developers’ guidelines. As a general rule, if more than 20% of the items of an instrument are missing the summary score will be assigned as missing. Missing data will be reported as part of the summary presentation of the raw data. Logistic regression will be used to explore whether participants with missing data have different characteristics than the completers or whether missing data can be assumed missing by random.

**Procedures for data checking and entering**

Data will be double data entered, and data validation will take place according to the procedures set
out in the data management plan and data validation plan. Prior to any statistical analysis, all variables will be checked for the number of missing values, impossible values and improbable values. Impossible and improbable values will be defined by clinical opinion. Improbable values will also include values that are outside three standard deviations of the mean value. Any questions regarding the data will go back to the data manager. Descriptive statistics will be calculated for all variables, and distributional assumptions will be checked.

The Standard Protocol Items-Recommendations for Interventional Trials (SPIRIT) table provides an overview of the study conduct, review, reporting and interpretation and is presented in Table 2. The final report will follow the Consolidated Standards of Reporting Trials (CONSORT), as well as the Template for Intervention Description and Replication (TIDieR).

Trial Status

The trial registration number is ClinicalTrials.govNCT03807518. Protocol Version 2 31st Oct 2019. The PERIOP-OG trial began recruitment on the 1st of March 2019. Anticipated end date is May 2020. To date 29 participants have been recruited.

List Of Abbreviations

NCT- Neoadjuvant chemotherapy,

MDT- Multi diciplinary team,

6 MWT- 6 minute walk test,

HRQoL- Health Related Quality of Life,

LOT-R- Life orientation Test-revised,

FACT-E- Functional Assessment of Cancer Therapy- Esophageal,

GSE- General Self Efficacy,

PMS- Pearlin Mastery Scale,

BMI- Body Mass Index,

POMS- Post Operative Morbidity Score,

CD Classification- Clavien-Dindo Classification,

WCC- White Cell Count,
CRP- C-Reactive Protein,
QALY- Quality adjusted life year,
NMB- Net monetary benefit,
SPIRIT- Standard Protocol Items-Recommendations for Intervventional Trials,
CBEP- Centre based exercise programme,
HBEP- Home based exercise programme,
REP- Rate of Perceived exertion.

Declarations

**Conflict of interests**
The authors declare no conflict of interests.

**Ethics approval and consent to participate**
Beaumont Hospital Ethics (Medical Research) Committee REC Ref: 18/58
Dublin City University Research Ethics Committee Ref: DCUREC/2018/255
University Hospital Galway Clinical Research Ethics Committee Ref: C.A 2160
Mercy Hospital Cork CREC Review Reference Number: ECM 4 (mm) 19/04/19
Waterford Institute of Technology REF:WIT2019REC0011

Informed consent to participate will be obtained from all study participants.
Ethical approval has been sought at both central and local levels. No recruitment took place until ethical approval was granted.

**Consent for publication**
Not Applicable

**Availability of data and materials**
The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.

**Competing interests**
All authors declare that they have no competing interests.

**Funding**
Some assistance for this project has been granted from the Beaumont Hospital Foundation Trust to cover the cost of exercise sessions in participating centres. 

Additionally, the Oesophageal Cancer Fund (the Irish National charity for oesophageal cancer in Ireland) have also provided the study with some funding. The Beaumont Cancer Foundation Trust and the Oesophageal Cancer Fund had no role in the design of the study or collection, analysis, and interpretation of data or in writing the manuscript. 

Authors' contributions

WBR and LL conceived the study. WBR, LL, RT, JB, CC, OM, PAC, PG, CT, TM, NMcC, MA, and JS contributed to study design. The drafted manuscript underwent revision by all authors. All authors read and approved the final manuscript.

References

1. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-57.

2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England journal of medicine. 2006;355(1):11-20.

3. Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet Oncology. 2015;16(9):1090-8.

4. Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature reviews Clinical oncology. 2015;12(4):213-26.
5. Jack S, West MA, Raw D, Marwood S, Ambler G, Cope TM, et al. The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014;40(10):1313-20.

6. Sinclair R, Navidi M, Griffin SM, Sumpter K. The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma. Annals of the Royal College of Surgeons of England. 2016;98(6):396-400.

7. Whibley J, Peters CJ, Halliday LJ, Chaudry AM, Allum WH. Poor performance in incremental shuttle walk and cardiopulmonary exercise testing predicts poor overall survival for patients undergoing esophago-gastric resection. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018;44(5):594-9.

8. Hijazi Y, Gondal U, Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. International journal of surgery. 2017;39:156-62.

9. Hoogeboom TJ, Oosting E, Vriezekolk JE, Veenhof C, Siemonsma PC, de Bie RA, et al. Therapeutic validity and effectiveness of preoperative exercise on functional recovery after joint replacement: a systematic review and meta-analysis. PloS one. 2012;7(5):e38031.

10. Hulzebos EH, Smit Y, Helders PP, van Meeteren NL. Preoperative physical therapy for elective cardiac surgery patients. The Cochrane database of systematic reviews. 2012;11:CD010118.

11. Avendano CE, Flume PA, Silvestri GA, King LB, Reed CE. Pulmonary complications after esophagectomy. The Annals of thoracic surgery. 2002;73(3):922-6.

12. Fagevik Olsen M, Wennberg E, Johnsson E, Josefson K, Lonroth H, Lundell L.
Randomized clinical study of the prevention of pulmonary complications after thoracoabdominal resection by two different breathing techniques. The British journal of surgery. 2002;89(10):1228-34.

13. Feeney C, Hussey J, Carey M, Reynolds JV. Assessment of physical fitness for esophageal surgery, and targeting interventions to optimize outcomes. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2010;23(7):529-39.

14. Valkenet K, Trappenburg JC, Gosselink R, Sosef MN, Willms J, Rosman C, et al. Preoperative inspiratory muscle training to prevent postoperative pulmonary complications in patients undergoing esophageal resection (PREPARE study): study protocol for a randomized controlled trial. Trials. 2014;15:144.

15. Lyden K, Kozey Keadle SL, Staudenmayer JW, Freedson PS. Validity of two wearable monitors to estimate breaks from sedentary time. Medicine and science in sports and exercise. 2012;44(11):2243-52.

16. Ferguson MK, Celauro AD, Prachand V. Prediction of major pulmonary complications after esophagectomy. The Annals of thoracic surgery. 2011;91(5):1494-500; discussion 500-1.

17. Correa-Gallego C, Gonen M, Fischer M, Grant F, Kemeny NE, Arslan-Carlon V, et al. Perioperative complications influence recurrence and survival after resection of hepatic colorectal metastases. Annals of surgical oncology. 2013;20(8):2477-84.

18. Jack S, West M, Grocott MP. Perioperative exercise training in elderly subjects. Best practice & research Clinical anaesthesiology. 2011;25(3):461-72.

19. O'Neill LM, Guinan E, Doyle SL, Bennett AE, Murphy C, Elliott JA, et al. The RESTORE Randomized Controlled Trial: Impact of a Multidisciplinary Rehabilitative Program on Cardiorespiratory Fitness in Esophagogastric cancer Survivorship. Annals of surgery.
20. Bolger JC, Loughney L, Tully R, Cunningham M, Keogh S, McCaffrey N, et al. Perioperative prehabilitation and rehabilitation in esophagogastric malignancies: a systematic review. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus. 2019.

21. Gilles Caty EP. Prehabilitation in Patients With Esophageal or Gastric Cancers. Clinicaltrialsgov Identifier: NCT02850172. 2019.

22. Roy BL. Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial (PREHAB). Clinicaltrialsgov Identifier: NCT02780921 [Internet]. 2017.

23. Trotter SM. HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery (HOPE) Clinicaltrialsgov Identifier: NCT03642093 [Internet]. 2018.

24. Sophie Allen JS. Does Prehabilitation Improve Exercise Performance and Insulin Resistance After Surgery for Oesophago-gastric Cancer? Clinicaltrialsgov Identifier: NCT02950324 2016.

25. Shim YM. Impact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer Patients. Clinicaltrialsgov Identifier: NCT03231462 [Internet]. 2018.

26. Chen CC-H. Effects of a “Walk, Eat, & Breathe” Nursing Intervention For Patients With Esophageal Cancer. Clinicaltrialsgov Identifier: NCT02850172 [Internet]. 2017.

27. Andrew Davies JZ. Prehabilitation of Patients With Esophageal Malignancy Undergoing Peri-operative Treatment (Pre-EMPT). Clinicaltrialsgov Identifier: NCT03626610. 2018.

28. Low DE, Alderson D, Cecconello I, Chang AC, Darling GE, D'Journo XB, et al.
International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). Annals of surgery. 2015;262(2):286-94.

29. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Medicine and science in sports and exercise. 2011;43(7):1334-59.

30. Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1447-78.

31. Pecorelli N, Fiore JF, Jr., Gillis C, Awasthi R, Mappin-Kasirer B, Niculiseanu P, et al. The six-minute walk test as a measure of postoperative recovery after colorectal resection: further examination of its measurement properties. Surgical endoscopy. 2016;30(6):2199-206.

32. Moran J, Wilson F, Guinan E, McCormick P, Hussey J, Moriarty J. The preoperative use of field tests of exercise tolerance to predict postoperative outcome in intra-abdominal surgery: a systematic review. J Clin Anesth. 2016;35:446-55.

33. Netz Y, Ayalon M, Dunsky A, Alexander N. 'The multiple-sit-to-stand' field test for older adults: what does it measure? Gerontology. 2004;50(3):121-6.

34. Yu R, Ong S, Cheung O, Leung J, Woo J. Reference Values of Grip Strength, Prevalence of Low Grip Strength, and Factors Affecting Grip Strength Values in Chinese Adults. Journal of the American Medical Directors Association. 2017;18(6):551.e9-.e16.
35. Hall DE, Arya S, Schmid KK, Blaser C, Carlson MA, Bailey TL, et al. Development and Initial Validation of the Risk Analysis Index for Measuring Frailty in Surgical Populations. JAMA surgery. 2017;152(2):175-82.

36. Scheier MF, Carver CS, Bridges MW. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. Journal of personality and social psychology. 1994;67(6):1063-78.

37. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Annals of medicine. 2001;33(5):337-43.

38. Darling G, Eton DT, Sulman J, Casson AG, Celia D. Validation of the functional assessment of cancer therapy esophageal cancer subscale. Cancer. 2006;107(4):854-63.

39. Theunissen M, Peters ML, Schouten EG, Fiddelers AA, Willemsen MG, Pinto PR, et al. Validation of the surgical fear questionnaire in adult patients waiting for elective surgery. PloS one. 2014;9(6):e100225.

40. Pearlin LI, Schooler C. The structure of coping. Journal of health and social behavior. 1978;19(1):2-21.

41. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer treatment reviews. 2013;39(5):534-40.

42. Timon CM, van den Barg R, Blain RJ, Kehoe L, Evans K, Walton J, et al. A review of the design and validation of web- and computer-based 24-h dietary recall tools. Nutrition research reviews. 2016;29(2):268-80.

43. Grocott MP, Browne JP, Van der Meulen J, Matejowsky C, Mutch M, Hamilton MA, et al. The Postoperative Morbidity Survey was validated and used to describe morbidity after major surgery. Journal of clinical epidemiology. 2007;60(9):919-28.

44. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The
Clavien-Dindo classification of surgical complications: five-year experience. Annals of surgery. 2009;250(2):187-96.

45. Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BPL, Breitenstein S, et al. The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials. Ann Surg. 2014;260(5):757-63.

46. Minnella EM, Awasthi R, Loiselle SE, Agnihotram RV, Ferri LE, Carli F. Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. JAMA surgery. 2018;153(12):1081-9.

47. Hobbins A, Barry L, Kelleher D, Shah K, Devlin N, Goni JMR, et al. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. PharmacoEconomics. 2018;36(11):1345-53.

48. Dettling DS, van der Schaaf M, Blom RL, Nollet F, Busch OR, van Berge Henegouwen MI. Feasibility and effectiveness of pre-operative inspiratory muscle training in patients undergoing oesophagectomy: a pilot study. Physiotherapy research international : the journal for researchers and clinicians in physical therapy. 2013;18(1):16-26.

49. Valkenet K, Trappenburg JC, Schippers CC, Wanders L, Lemmens L, Backx FJ, et al. Feasibility of Exercise Training in Cancer Patients Scheduled for Elective Gastrointestinal Surgery. Digestive surgery. 2016;33(5):439-47.

50. Valkenet K, Trappenburg JCA, Ruurda JP, Guinan EM, Reynolds JV, Nafteux P, et al. Multicentre randomized clinical trial of inspiratory muscle training versus usual care before surgery for oesophageal cancer. The British journal of surgery. 2018;105(5):502-11.

51. van Adrichem EJ, Meulenbroek RL, Plukker JT, Groen H, van Weert E. Comparison of
two preoperative inspiratory muscle training programs to prevent pulmonary complications in patients undergoing esophagectomy: a randomized controlled pilot study. Annals of surgical oncology. 2014;21(7):2353-60.

52. Xu YJ, Cheng JC, Lee JM, Huang PM, Huang GH, Chen CC. A Walk-and-Eat Intervention Improves Outcomes for Patients With Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy. The oncologist. 2015;20(10):1216-22.

53. Yamamoto K, Nagatsuma Y, Fukuda Y, Hirao M, Nishikawa K, Miyamoto A, et al. Effectiveness of a preoperative exercise and nutritional support program for elderly sarcopenic patients with gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017;20(5):913-8.

54. Christensen JF, Simonsen C, Banck-Petersen A, Thorsen-Streit S, Herrstedt A, Djurhuus SS, et al. Safety and feasibility of preoperative exercise training during neoadjuvant treatment before surgery for adenocarcinoma of the gastro-oesophageal junction. BJS Open. 2018.

55. Awdeh H, Kassak K, Sfeir P, Hatoum H, Bitar H, Husari A. The SF-36 and 6-Minute Walk Test are Significant Predictors of Complications After Major Surgery. World journal of surgery. 2015;39(6):1406-12.

56. Shulman MA, Cuthbertson BH, Wijeysundera DN, Pearse RM, Thompson B, Torres E, et al. Using the 6-minute walk test to predict disability-free survival after major surgery. British journal of anaesthesia. 2019;122(1):111-9.

57. Chasen MR, Bhargava R. A rehabilitation program for patients with gastroesophageal cancer--a pilot study. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2010;18 Suppl 2:S35-40.

58. O’Neill L GE, Doyle SL, Elliott JA, O’Sullivan J, Reynolds JV, Hussey J. Rehabilitation
strategies following esophageal cancer (the ReStOre trial): a feasibility study.

Diseases of the Esophagus. 2017;30(5):1-8.

Tables

Table 1. Timeline of assessments in the PERIOP-OG trial

| Outcomes                        | Assessment Measure | Baseline | Post NCT | Approx.1 week before surgery | Day 3 post-op | Day 5 post-op | 4 weeks post-op | 10 weeks post-op |
|---------------------------------|--------------------|----------|----------|-------------------------------|---------------|---------------|----------------|------------------|
| Primary Endpoint-cardiorespiratory fitness | 6 MWT              | X        | X        | X                             | X             | X             | X              | X                |
| Secondary Endpoints             |                    |          |          |                               |               |               |                |                  |
| Physical Health-Strength        | Sit to stand test  | X        | X        | X                             | X             | X             | X              | X                |
|                                 | Grip strength      |          |          |                               |               |               |                |                  |
| Activity Behaviors              | Accelerometer      | X        | X        | X                             | X             | X             | X              | X                |
| Body Composition                | BMI                | X        | X        | X                             | X             | X             | X              | X                |
| Psychological Health-Optimism   | LOT-R              | X        |          |                               |               |               |                |                  |
| HRQoL                           | EQ-5D/FACT/        | X        | X        | X                             | X             | X             | X              | X                |
| Exploratory Endpoints |
|------------------------|
|**Clinical Health-Nutrition** |
| GPS X X X X X X |
| Sarcopenia score X X X X |
| Foodbook 24 X X X |

**Morbidity**

| POMS |
|------|
| X X |

**Inflammatory Markers**

| WCC, CRP |
|---------|
| X X X X |

Abbreviations: NCT neoadjuvant chemotherapy, 6 MWT- 6 minute walk test, BMI- Body Mass Index, LOT-R- Life orientation Test-revised, QoL- Quality of Life, FACT-E- Functional Assessment of Cancer Therapy- Esophageal, GSE PMS General Self Efficacy Pearlin Mastery Scale, SFQ- Surgical Fear Questionnaire, GPS- Glasgow Prognostic Score, POMS- Post Operative Morbidity Score, CD Classification- Clavien-Dindo Classification, WCC- White Cell Count, CRP-C-Reactive Protein.

Table 2. The Standard Protocol Items-Recommendations for Interventional Trials (SPIRIT)
The effect of a pre- and post-operative exercise programme versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (The PERIOP-OG Trial): Study protocol for a randomised controlled trial.

ClinicalTrials.gov Identifier: NCT03807518

Royal College of Surgeons Ireland, 123 St Stephens Green, Dublin, Ireland
Sponsor had no role in study design
Mr. William Robb, Principal Investigator
Dr. Noel McCarrfey, Co Investigator
Mr. Thomas Murphy, Co Investigator
Mr. Chris Collins, Co Investigator
Prof. Oliver McAnena, Co Investigator
Mr Paul A Carroll, Co Investigator
Introduction

Background and rationale

Oesophagogastric cancers are a considerable health burden. In the past 10 years the 5-year survival for both cancers has doubled. This is due to a number of factors including advances in neoadjuvant and adjuvant chemotherapy and radiotherapy. However, physical fitness significantly declines as a result of neoadjuvant and adjuvant therapy. From studies in other cancers it is known that perioperative training improves physical fitness, yet there is little research into its...
effects in those with upper oesophagogastric cancers. Therefore, the aim of the PERIOP-OG trial is to investigate the effects of a community-based exercise training programme (delivered in a leisure centre or at home dependent on patient location) pre- and post-operatively compared to usual care on cardiorespiratory fitness and other physical, psychological and clinical health outcomes in people with confirmed oesophagogastric cancer.

The usual-care control group (usual care – no formal exercise training) receive routine care throughout their cancer pathway from diagnosis to surgical resection. No specific advice about exercise training is offered.

Objectives

The aims of this study were to evaluate the following hypotheses:

Primary hypothesis: A structured community-based exercise programme compared with a usual care control group (usual care – no formal exercise training) will result in a clinically significant increase in cardiorespiratory fitness assessed using a 6-minute walk test assessed at the pre-surgery time point.
Secondary hypothesis:
a) A structured community-based exercise programme compared with a usual care control group (usual care – no formal exercise training) will result in an improvement in cardiorespiratory fitness post-operatively in addition to other physical health outcomes assessed using upper and lower body strength tests, physical activity monitoring, body mass index, frailty assessed at several time points throughout the study.
b) A structured community-based exercise programme compared with a usual care control group (usual care – no formal exercise training) will result in an improvement in psychological health assessed using health related quality of life questionnaire and semi structured interviews assessed at several time points throughout the study.

Exploratory hypothesis: A structured community-based exercise programme compared with a usual care control group (usual care – no formal exercise training) will result in an improvement in health economy assessed using a questionnaire and clinical health assessed using post-operative morbidity and hospital length of stay, nutritional status, immune and inflammatory
Trial design

Methods: Participants, interventions, and outcomes

Study setting

Eligibility criteria

markers, as well as cancer staging assessed at several time points throughout the study.

Parallel group randomised 1:1 controlled multi centre trial.

There are three Irish Health Services Executive (HSE) hospitals recruiting to this trial: Beaumont Hospital Dublin, Mercy University Hospital Cork (MUHC) and University Hospital Galway (UHG). Assessments and exercise training is being delivered in several sites. For Beaumont hospital Dublin: ExWell Medical; for MUHC, to cater for a large area: Cork Leisure World, Waterford Institute of Technology, Heartwise for Health and University of Limerick; and for UHG, Cancer Care West gym.

Eligibility criteria for inclusion at cancer diagnosis include the following: age ≥ 18 years, with multidisciplinary team (MDT) referral for neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy (NCT) prior to planned oesophagectomy or gastrectomy; with confirmed MDT evidence of adenocarcinoma or squamous cell cancer of the oesophagus, oesophago-gastric junction or stomach.
requiring planned surgical resection; with recorded measurement (endoscopic or otherwise) that the tumour starts more than 5cm below cricopharyngeus. Exclusion criteria include the following: inability to give informed consent, inability to participate in exercise training (unable to perform 6MWT), patients with high grade dysplasia (squamous cell or adenocarcinoma); distant metastatic disease at time of enrolment or during their NCT therapy; Evidence of previous/concomitant malignancy that would interfere with this treatment protocol; Pregnancy. Figure 1 provides an algorithm of the clinical pathway and complete series of assessment for the duration of the trial.

Participants are randomised (1:1) to either a structured exercise training programme or usual care control group at baseline. The intervention will be discontinued for a given participant should they no longer wish to participate. Strategies to improve adherence to intervention protocols. The participants will meet the instructors face to face at the structured exercise sessions.
Additionally, they will receive phone calls from the team to monitor their progress and answer any questions they may have on a regular basis. All routine cancer care is permitted for both groups.

Outcomes

The primary endpoint is cardiorespiratory fitness measured by the 6-minute walk test assessed at the pre-surgery time point. Secondary endpoints include measurement of cardiorespiratory fitness measured post-operatively and physical health assessed using upper and lower body strength tests, physical activity monitoring, body mass index, frailty, psychological health: assessed using health related quality of life questionnaire and semi structured interviews. Exploratory endpoints include health economy and clinical health assessed using post-operative morbidity and hospital length of stay, nutritional status, immune and inflammatory markers, as well as cancer staging.

Participant timeline

Outcome measurements are taken for all participants at baseline, post NCT, pre surgery, 3 days post-surgery, 5 days post-surgery, 4 weeks post-surgery and 10 weeks post-surgery.

Sample size

The sample size calculation was based on results.
from the Minella et al. study which identified a pre-operative score gain in 6MWT of 60m from a baseline score of 450m (standard deviation 85m) an approximate 13% improvement. Assuming a similar baseline score, a 15% score gain can be detected with p-value of 0.05 and power 80% with a sample of 26 participants in 2 groups. With an anticipated 20% drop-out, recruitment of 62 participants is anticipated.

Inclusion of 3 clinical sites and 7 exercise sites with the additional option of a home programme.

Methods: Assignment of interventions (for controlled trials)

Allocation concealment mechanism

Randomisation is performed using a central data management to generate a random allocation sequence (1:1). Randomisation allocation and areas stored in opaque envelopes at the lead exercise site (ExWell Medical, Dublin). Due to the nature of the study, blinding of patients or physiological assessors is not possible.

Implementation
Methods: Data collection, management, and analysis

Data collection methods

18a The outcomes are listed in Table 1: Outcomes and Assessment Measures.

18b The participants are contacted by telephone curing the intervention to promote participant retention and complete follow-up. Baseline data to be collected for participants who discontinue or deviate from intervention protocols, unless they withdraw consent.

Data management

19 Data will be double data entered, and data validation will take place according to the procedures set out in the data management plan and data validation plan. Prior to any statistical analysis, all variables will be checked for the number of missing values, impossible values and improbable values. Impossible and improbable values will be defined by clinical opinion. Improbable values will also include values that are outside three standard deviations of the mean value. Any questions regarding the data will go back to the data manager. Descriptive statistics will be calculated for all variables, and distributional assumptions will be checked.

Statistical methods

20a The analysis will be performed as an intention-to-treat analysis. No interim analysis will be conducted. Data validity will be conducted prior to analysis and corrected as appropriate. This includes tabulation of discrete score values and graphical representation of continuous variables (e.g., histograms and box plots). The study population will be described separately for two randomised groups using variables obtained at baseline. The variables will be described as mean (SD) and numbers (%) as appropriate. The primary analysis of the primary outcome will be conducted as t-tests of independent group mean differences in 6MWT at each time point. The mean difference and 95% confidence interval will be reported and illustrated graphically. Individual change in 6MWT will be calculated from baseline and compared at different time points using t-tests. In addition, binary outcome variables indicating ability of walk more than
The combined median distance at baseline will be constructed and the group distribution will be tested at different time points using chi-squared tests.

The secondary analysis of the primary outcome will use mixed-level analysis with intervention group, time point and interaction of intervention and time points. This analysis will include baseline score for the outcome measure as covariate. The estimated parameter for the interaction variables will be interpreted as the difference-in-difference between the two groups over time. A separate analysis will explore potential differences in the intervention group between participants who received the intervention at a training centre and those who trained at home. This analysis will be expanded to include descriptive baseline variables such as sex and age. The secondary analysis will use mixed-level analysis and include baseline score and baseline characteristics as covariates.

The cost-effectiveness analysis will be conducted from a societal perspective over the duration of the trial period. No extrapolation of long-term economic outcomes is planned. The EQ-5D-5L data reported at each time point will be used to estimate quality-adjusted life years using time-weighted utility scores. The utility scores will be calculated for each individual at each data point using the Irish scoring algorithm for EQ-5D-5. The area under the curve denotes the QALY and incremental QALY is determined as the mean group difference.

Cost of the intervention and subsequent resource use will be calculated for each individual using average cost per participant for the intervention programme and self-reported data on healthcare utilisation. Unit costs will be obtained from national sources and assigned to the resource utilisation and aggregated over the whole trial period for each individual. Net monetary benefit (NMB) will be estimated as the cost minus the QALY gain multiplied by an assumed threshold value per QALY. The NMB estimates will also be analysed using regression methods to account for variation in group characteristics and to identify sub-populations where the intervention might have incremental cost-effectiveness ratio.

Participants with missing data either because of early drop-out, loss to follow-up or missed participation in the data collection can bias the results. By design there will be no missing data at baseline because only participants with complete baseline data will be randomised. Missing variables in outcome
measures will be handled according to instrument developers’ guidelines. As a general rule, if more than 20% of the items of an instrument are missing the summary score will be assigned as missing. Missing data will be reported as part of the summary presentation of the raw data. Logistic regression will be used to explore whether participants with missing data have different characteristics than the completers or whether missing data can be assumed missing by random. If a pattern in missing data can be observed missing data will be handled using “multiple imputation” techniques where missing variables are predicted in multiple dataset using descriptive variables identified as important covariates for missing data (sex, age, intervention group and baseline score).

Methods: Monitoring

Data monitoring 21a

Data is monitored after the first complete patient at each site to ensure high quality data. Data will be double data entered, and data validation will take place according to the procedures set out in the data management plan and data validation plan. Prior to any statistical analysis, all variables will be checked for the number of missing values, impossible values and improbable values. Impossible and improbable values will be defined by clinical opinion. Improbable values will also include values that are outside three standard deviations of the mean value. Any questions regarding the data will go back to the data manager. Descriptive statistics will be calculated for all variables, and distributional assumptions will be checked.

Harms 22

There will be no interim analysis conducted.

Auditing 23

Adverse events will be recorded in the relevant case report form by the researcher. Fatal or life-threatening serious adverse events are reported within 24 hours of the research team becoming aware of the event. The serious adverse events form documents the nature of the event, date of onset, severity, corrective therapies given, outcome and causality (i.e. unrelated, unlikely, possibly, probably, definitely). And queries relating to adverse event reporting will be directed to the chief investigator in the first instance.

Will comply completely with any auditing processes required by sponsor.
Ethics and dissemination

Research ethics approval 24
Beaumont Hospital Ethics (Medical Research) Committee REC Ref: 18/58
Dublin City University Research Ethics Committee Ref: DCUREC/2018/255
University Hospital Galway Clinical Research Ethics Committee Ref: C.A 2160
Mercy Hospital Cork CREC Review Reference Number: ECM 4 (mm) 19/04/19
Waterford Institute of Technology REF:WIT2019REC0011

Protocol amendments 25
All site leads will be contacted by telephone if there is a significant amendment to the protocol. The amended protocol will then be emailed to all site leads.

Consent or assent 26a
The study will be discussed with patients after their initial diagnosis is known, but before neo-adjuvant treatment has started. No patient will have the study discussed with them on the day that they find out their diagnosis. Potentially eligible patients will have the study discussed with them by the principal investigator, or a nominated senior non-consultant hospital doctor at their next OPD appointment. Interested patients will receive an information leaflet and consent form for the study. After a period of 48 hours, patients will be contacted by telephone to confirm their interest in the study. Consent forms will be signed at their patient visit.

26b
Additional explicit consent will be sought for collection and use of participant data and biological specimens in ancillary studies.

Confidentiality 27
Data will be entered with all direct patient identifiers removed; patients will be identified by study codes. All physiological data are held in an encrypted format. All data will be stored on a secure password protected desktop in a secured locked room.

Declaration of interests 28
The authors declare that they have no competing interests

Access to data 29
The data will only be accessed by the designated members of the research team.

Ancillary and post-trial care 30
Post-trial the structured exercise classes will continue and participants may continue to use the facilitates

Dissemination policy 31a
The results will be published in peer reviewed journals and disseminated at conferences and scientific meeting internationally. The findings
of the trial will also be published in patient information magazines and booklets as informed with the help of the patient public involvement group.

31b

Authorship eligibility guidelines will be discussed and agreed with all contributors prior to publication and the use of professional writers is not intended.

31c

There are no plans for granting public access to the full protocol, participant-level dataset, and statistical code.

Appendices

| Informed consent materials | Model consent form and other related documentation given to participants and authorised surrogates |
|---------------------------|--------------------------------------------------------------------------------------------------------|
| Biological specimens      | Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable (N/A) |

Figures
Figure 1

An algorithm of the clinical pathway and the timepoints for assessments during the trial

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

SPIRIT_Feb 2020.doc